Three single-arm trials have reported the addition of ICB to first-line standard therapy in metastatic MSS-CRC, with median PFS 11.1 months (RAS/BRAF-wildtype cases) [27], 9.8 months (RAS/BRAF-mutant cases) [28] and 8.2 months (RAS-mutant cases) [29]. The gene discussed is BRAF; the disease is colorectal carcinoma.